Sarepta Therap.


Sarepta Therapeutics: The Stock Will Face Near-Term Pressure, Says Cowen

Cowen analyst Ritu Baral reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $19, as the company announced data through Week 168 …

UPDATE: We Remain Cautious Near Term On Shares Of Sarepta Therapeutics, Says Canaccord

In a research report sent to investors today, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) with a …

Sarepta Shares Offer A Compelling Entry Point For Long-Term Investors, Says Roth Capital

In a research report released this morning, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts